The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin

Abstract

Aim: To determine whether the SNP rs4149056 in SLCO1B1 alters the pharmacodynamics of pravastatin. Methods: rs4149056 was genotyped in 626 pravastatin-treated participants in the WOSCOPS trial and the response after 1 year of treatment was compared between the different genotypes. Results: Pravastatin reduced serum LDL cholesterol by 22.2% in TT homozygotes, by 22.2% in TC heterozygotes and by 17.7% in CC homozygotes (TT + TC vs. CC Pvalue 0.33). There were no significant differences in the response of total cholesterol, LDL, HDL, triglycerides or CRP to pravastatin between the genotypes. Conclusion: The rs4149056 SNP did not significantly affect the pharmacodynamics of pravastatin. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.